Clinical Trial Update: Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating adjuvant PVX-410 vaccine in combination with durvalumab for stage II/III triple-negative breast cancer; trial status is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• PVX-410 vaccine

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Breast Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING